Risultati per: Linea guida sulla diagnosi e trattamento dell’Helicobacter pylori

Un servizio per le donne nelle prime settimane di gravidanza

Studio pubblicato nella rivista Nature Communications

Studio della Karolinska Institutet con l’Università Milano-Bicocca

Screening for, and treating, Helicobacter pylori (H. pylori) in the general population or patients with early gastric neoplasia could reduce incidence of, and mortality from, gastric cancer. We updated a meta-analysis of randomized controlled trials (RCTs) examining this issue.

Un terzo dei pazienti finisce in una casa di cura entro 3 anni

Un terzo dei pazienti finisce in una casa di cura entro 3 anni

Ascierto, il 50% dei pazienti metastatici sopravvive a 10 anni dalla diagnosi

Analisi potrebbe individuare primissimi segni cellule cancerose

Fimmg denuncia “gravi ritardi negli aggiornamenti degli elenchi

Fimmg denuncia “gravi ritardi negli aggiornamenti degli elenchi

Rinviato a metà gennaio voto su piano revisione Rete oncologica

Introduction
Helicobacter pylori is a major health problem, with the high prevalence of H. pylori and the increasing antibiotic resistance rate in China. Antibiotic resistance is the main reason for the failure of H. pylori eradication. This study aims to evaluate the efficacy and safety of susceptibility-guided quadruple therapy with antibiotic resistance using the string test coupled with quantitative PCR (qPCR) for H. pylori eradication.

Methods and analysis
This is a multicentre, open, randomised clinical trial that will enroll 324 patients with H. pylori infection. Patients will be randomised to two groups for a 14-day treatment: Treatment group will be treated with proton pump inhibitor (PPI), bismuth with two different kinds of antibiotics susceptibly guided by string test coupled with qPCR, while control group will be treated empirically with PPI, bismuth with two different kinds of antibiotics. The types and dosages of bismuth, PPI and antibiotics administered in this trial are based on the 2022 Chinese Guidelines for the treatment of H. pylori infection and the Sixth Chinese National Consensus Report on the management of H. pylori infection. The primary endpoint is the eradication rate, while secondary endpoints include compliance, the incidence of adverse events and adverse drug reactions.

Ethics and dissemination
This study was approved by the ethics committee of the Third People’s Hospital of Zhengzhou (No. 2024-04-001-K02). The results will be published in the appropriate peer-reviewed journal.

Trial registration number
ChiCTR2400082768.